BDB018 / Seven and Eight BioPharma, Eikon Therap - LARVOL DELTA

KEYNOTE-D26: Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=1 | Completed | Sponsor: Eikon Therapeutics | Active, not recruiting ➔ Completed | Trial completion date: Mar 2025 ➔ Sep 2024 | Trial primary completion date: Dec 2024 ➔ Mar 2024

Monotherapy • Trial completion • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

KEYNOTE-D26: Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=1 | Active, not recruiting | Sponsor: Eikon Therapeutics | Trial completion date: Mar 2024 ➔ Mar 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Combination therapy • Metastases • Monotherapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=1 | Active, not recruiting | Sponsor: Eikon Therapeutics | Recruiting ➔ Active, not recruiting | N=50 ➔ 1 | Trial completion date: Dec 2023 ➔ Mar 2024 | Trial primary completion date: Mar 2023 ➔ Dec 2023

Combination therapy • Enrollment change • Enrollment closed • Metastases • Monotherapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Seven and Eight Biopharmaceuticals Announces Exclusive Clinical License Agreement with Eikon Therapeutics to Develop and Commercialize TLR7/8 dual agonists (Businesswire) - "Seven and Eight Biopharmaceuticals...announced today that it has signed an exclusive licensing agreement with Eikon Therapeutics. As part of the agreement, Eikon Therapeutics is awarded global rights to develop and commercialize the company’s novel immune modulator agonists targeting toll-like receptor 7 and 8 (TLR7/8)....The exclusive licensing agreement also includes development of novel Toll-like receptor ligand antibody conjugation (TLAC) molecules."

Licensing / partnership • Oncology • Solid Tumor

Seven and Eight Biopharmaceuticals Inc. Announces the First Patient Treated in a First-in-Human Clinical Trial of the TLR7/8 dual agonist BDB018 in Advanced Solid Tumors (Businesswire) - "'We are excited to bring our next generation program with an intravenously administered TLR 7/8 dual agonist to the clinic, building on our success with BDB001,' said Dr. Robert H.I. Andtbacka....'The dosing of the first patient with BDB018 will begin to provide us with essential safety information needed to guide the future development of BDB018.'"

P1 data

Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=50; Recruiting; Sponsor: Seven and Eight Biopharmaceuticals Inc; Not yet recruiting ➔ Recruiting

Clinical • Combination therapy • Enrollment open • Monotherapy • Oncology • Solid Tumor

Seven and Eight Biopharmaceuticals Inc. Announces the First Patient Treated in a First-in-Human Clinical Trial of the TLR7/8 dual agonist BDB018 in Advanced Solid Tumors (Businesswire) - "Seven and Eight Biopharmaceuticals Inc...announced today that the first patient was treated in a First-in-Human Phase 1 clinical trial evaluating BDB018 in advanced solid tumors at Florida Cancer Specialists & Research Institute in Sarasota, FL....BDB018-101 (NCT04840394) is an open-label, dose escalation Phase I clinical trial evaluating the safety and tolerability of BDB018 in patients with advanced solid tumors that have relapsed or are refractory to standard treatments."

Trial status • Oncology • Solid Tumor

Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=50; Not yet recruiting; Sponsor: Seven and Eight Biopharmaceuticals Inc

New P1 trial • Oncology • Solid Tumor